Isaly Samuel D
10% owner at PVLA; Director at Loxo Oncology, Inc.; 10% owner at Audentes Therapeutics, Inc., and 12 more
- Sold, on record
- $431M
- Dollars the filings state
- Form 4 sales
- 30
- Latest Jan 3, 2018
- Form 144 notices
- 0
- Proposed sales
- Companies
- 15
- Filed as an executive or holder
Companies
- PVLAPALVELLA THERAPEUTICS, INC.10% owner
- Loxo Oncology, Inc.Director
- Audentes Therapeutics, Inc.10% owner
- Roka BioScience, Inc.10% owner
- GKOSGLAUKOS CorpDirector
- Relypsa Inc10% owner
- Sientra, Inc.10% owner
- INTERCEPT PHARMACEUTICALS INCDirector
- Mirati Therapeutics, Inc.10% owner
- SUPNSUPERNUS PHARMACEUTICALS, INC.10% owner
- AMRNAMARIN CORP PLC\UKDirector
- Anthera Pharmaceuticals IncDirector
- PCRXPacira BioSciences, Inc.10% owner
- NxStage Medical, Inc.Director
- DOV PHARMACEUTICAL INCDirector
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- Relypsa Inc5.5M shares
- AMRN4.3M shares
- PVLA1.7M shares
- Anthera Pharmaceuticals Inc1.5M shares
- DOV PHARMACEUTICAL INC817,771 shares
- Sientra, Inc.733,697 shares
- Audentes Therapeutics, Inc.672,000 shares
- INTERCEPT PHARMACEUTICALS INC644,385 shares
- GKOS635,972 shares
- PCRX340,841 shares
- SUPN302,183 shares
- Loxo Oncology, Inc.270,000 shares
- Roka BioScience, Inc.127,601 shares
- Mirati Therapeutics, Inc.107,332 shares
- NxStage Medical, Inc.58,256 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Relypsa IncPlan not statedDec 23 2015
Sold 500,000 shares at $27.18 ($13.6M)
Isaly Samuel D, 10% owner
Sold 6.3% of holdings ($215M position)7.4M shares leftFiling
- 2 Form 4 sale Relypsa IncUnusualJul 25 +215 days
Sold 4M shares at $32.00 ($129M)
Isaly Samuel D, 10% owner
Sold 54.6% of holdings ($237M position)3.4M shares leftFiling
- 3 Form 4 sale GKOSUnusualMar 3 +221 days
Sold 55,772 shares at $47.05 ($2.6M)
Isaly Samuel D, Director
Sold 73.6% of holdings ($3.6M position)20,044 shares leftFirst sale on recordFiling
- 4 Form 4 sale GKOSUnusualSep 5 +186 days
Sold 580,200 shares at $38.73 ($22.5M)
Isaly Samuel D, Director
Sold 98.7% of holdings ($22.8M position)7,895 shares leftFiling
- 5 Form 4 sale Roka BioScience, Inc.UnusualSep 27 +22 days
Sold 127,601 shares at $0.98 ($126k)
Isaly Samuel D, 10% owner
Sold 95.2% of holdings ($132k position)6,379 shares leftFirst sale on recordFiling
- 6 Form 4 sale Audentes Therapeutics, Inc.Plan not statedSep 29 +2 days
Sold 672,000 shares at $28.25 ($19M)
Isaly Samuel D, 10% owner
Sold 14% of holdings ($136M position)4.1M shares leftFirst sale on recordFiling
- 7 Form 4 sale Loxo Oncology, Inc.Plan not statedNov 16 +48 days
Sold 270,000 shares at $74.26 ($20.1M)
Isaly Samuel D, Director
Sold 15.6% of holdings ($128M position)1.5M shares leftFirst sale on recordFiling
- 8 Form 4 sale PVLAUnusualJan 3 +48 days
Sold 1.7M shares at $7.35 ($12.6M)
Isaly Samuel D, 10% owner
Sold 97.2% of holdings ($12.9M position)49,270 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (30)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2018 | PVLA | 10% owner | Form 4 sale | 1.7M | $12.6M | 97.2% | Unusual | SEC |
| Nov 16, 2017 | Loxo Oncology, Inc. | Director | Form 4 sale | 270,000 | $20.1M | 15.6% | Plan not stated | SEC |
| Sep 29, 2017 | Audentes Therapeutics, Inc. | 10% owner | Form 4 sale | 672,000 | $19M | 14.0% | Plan not stated | SEC |
| Sep 27, 2017 | Roka BioScience, Inc. | 10% owner | Form 4 sale | 127,601 | $126k | 95.2% | Unusual | SEC |
| Sep 5, 2017 | GKOS | Director | Form 4 sale | 580,200 | $22.5M | 98.7% | Unusual | SEC |
| Mar 3, 2017 | GKOS | Director | Form 4 sale | 55,772 | $2.6M | 73.6% | Unusual | SEC |
| Jul 25, 2016 | Relypsa Inc | 10% owner | Form 4 sale | 4M | $129M | 54.6% | Unusual | SEC |
| Dec 23, 2015 | Relypsa Inc | 10% owner | Form 4 sale | 500,000 | $13.6M | 6.3% | Plan not stated | SEC |
| Oct 12, 2015 | Sientra, Inc. | 10% owner | Form 4 sale | 287,891 | $1.7M | 94.4% | Unusual | SEC |
| Oct 6, 2015 | Sientra, Inc. | 10% owner | Form 4 sale | 193,000 | $1.7M | 88.0% | Unusual | SEC |
| Oct 1, 2015 | Sientra, Inc. | 10% owner | Form 4 sale | 101,898 | $1M | 78.5% | Unusual | SEC |
| Sep 28, 2015 | Sientra, Inc. | 10% owner | Form 4 sale | 150,908 | $1.6M | 84.0% | Unusual | SEC |
| Mar 25, 2015 | INTERCEPT PHARMACEUTICALS INC | Director | Form 4 sale | 207,800 | $57M | 14.0% | Plan not stated | SEC |
| Aug 15, 2014 | Relypsa Inc | 10% owner | Form 4 sale | 990,000 | $26.1M | 10.0% | Plan not stated | SEC |
| Aug 14, 2014 | INTERCEPT PHARMACEUTICALS INC | Director | Form 4 sale | 60,000 | $18M | 3.6% | Plan not stated | SEC |
| Jul 1, 2014 | Mirati Therapeutics, Inc. | 10% owner | Form 4 sale | 107,332 | $2.3M | 8.4% | Plan not stated | SEC |
| Oct 15, 2013 | INTERCEPT PHARMACEUTICALS INC | Director, 10% owner | Form 4 sale | 376,585 | $23.5M | 17.5% | Plan not stated | SEC |
| Feb 13, 2013 | SUPN | 10% owner | Form 4 sale | 302,183 | $2.3M | 27.0% | Unusual | SEC |
| Jul 27, 2012 | AMRN | Director | Form 4 sale | 366,300 | $5.4M | 97.9% | Unusual | SEC |
| Jun 29, 2012 | Anthera Pharmaceuticals Inc | Director | Form 4 sale | 1.3M | $937k | 100.0% | Unusual | SEC |
| Mar 12, 2012 | PCRX | 10% owner | Form 4 sale | 100,100 | $1.1M | 3.9% | Plan not stated | SEC |
| Feb 3, 2012 | PCRX | 10% owner | Form 4 sale | 143,300 | $1.6M | 5.2% | Plan not stated | SEC |
| Nov 18, 2011 | Anthera Pharmaceuticals Inc | Director, 10% owner | Form 4 sale | 52,000 | $351k | 1.8% | Plan not stated | SEC |
| Oct 31, 2011 | PCRX | 10% owner | Form 4 sale | 97,441 | $1M | 3.4% | Plan not stated | SEC |
| May 18, 2011 | Anthera Pharmaceuticals Inc | Director, 10% owner | Form 4 sale | 181,334 | $1.5M | 5.5% | Plan not stated | SEC |
| May 2, 2011 | AMRN | Director | Form 4 sale | 132,900 | $2.1M | 88.5% | Unusual | SEC |
| Apr 20, 2011 | AMRN | Director | Form 4 sale | 3.8M | $58.2M | 99.3% | Unusual | SEC |
| Dec 9, 2010 | NxStage Medical, Inc. | Director | Form 4 sale | 2,356 | $53k | 100.0% | Unusual | SEC |
| Sep 9, 2010 | NxStage Medical, Inc. | Director, 10% owner | Form 4 sale | 55,900 | $933k | 1.3% | Plan not stated | SEC |
| May 16, 2006 | DOV PHARMACEUTICAL INC | Director | Form 4 sale | 817,771 | $2.7M | 76.0% | Unusual | SEC |